Stock Taper
SCREENER COMPARE ANY 2 STOCKS
TBPH
THERAVANCE BIOPHARMA INC
NASDAQ
$17.05
▲ UP 0.06% (0.01)

KEY STATISTICS

Market Cap$883.67 M
52w High$21.03
52w Low$13.08
Dividend Yield—
Frequency—
P/E-160.55
Volume414.57K
Shares Out.51.83M

COMPANY

LEADERSHIP

Rick E. Winningham
CHIEF EXECUTIVE
Rick E. Winningham

COMPENSATION 2026

Salary$1,047,431
Stock Awards$0
Incentive Plan Pay$419,182
All Other Comp.$5,406
Total$1,472,019

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 16, 2014
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
90

PRICE TARGET

Target High$17.00
Target Low$14.00
Target Median$15.50
Target Consensus$15.50

UPCOMING EARNINGS

DateNov 10, 2026
DayTuesday
Rev. Est.$21.95M
NOV
10
TUE

PRICE

$17.05 ▲ UP 0.06% (+$0.01)
$17.03$17.04$17.05$17.069:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM17.05

About Theravance Biopharma Inc

https://www.theravance.com ↗

Theravance Biopharma develops respiratory and inflammatory medicines, including YUPELRI for COPD and various investigational drugs for autoimmune, lung, and gastrointestinal diseases worldwide.

INDUSTRY

Biotechnology

A PRODUCT THERAVANCE BIOPHARMA INC IS KNOWN FOR

YUPELRI® (revefenacin)
YUPELRI® (revefenacin)

YUPELRI® is the first once-daily nebulized LAMA bronchodilator approved for COPD maintenance in the U.S. and China, providing a vital treatment option for patients worldwide.

COMPETITORS

COMPETITOR
AZN COMPARE
GSK COMPARE
NVS COMPARE
REGN COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
YUPELRI Monotherapy— $24.7M $21.85M ▼—
Collaborative Arrangement Revenue$19.99M — — $20.73M ▲
License$7.5M — — —

Revenue by Geography

MapREGIONFY2022FY2023FY2024FY2025
UNITED STATES$51.12M $57.2M ▲$64.38M ▲$74.96M ▲
Europe$222K $223K ▲— $32.5M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
126
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.00% · 1.3M
XSU.TO
0.02% · 1.0M
XPH
0.89% · 307.5K
VETS
0.14% · 289.8K
SCHA
0.01% · 176.9K
DFAC
0.00% · 141.8K
JSML
0.60% · 132.0K
FSMD
0.09% · 131.1K
BBP
1.26% · 88.0K
PSC
0.04% · 70.4K
GSSC
0.11% · 68.8K
SBIO
0.45% · 63.8K
NUSC
0.05% · 40.2K
XRS2.F
0.02% · 36.9K
MNA
0.24% · 36.3K
JPSE
0.09% · 32.8K
PRFZ
0.02% · 28.3K
RSSL
0.02% · 19.1K
FSML
0.21% · 18.7K
PILL
0.60% · 8.7K
TILT
0.00% · 4.3K
BIB
0.03% · 1.8K
AVSU
0.01% · 1.6K
KBFR
0.05% · 314
USFMDN.MX
0.00% · 155
RESM
0.04% · 139

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
286
TOP 12 OF 286 · RANKED BY POSITION SIZE
Woodford Investment Management Ltd
11.4M sh · $221.11M
Madison Avenue Partners, LP
9.5M sh · $177.95M
Weiss Asset Management LP
7.5M sh · $126.77M
Newtyn Management, LLC
5.0M sh · $72.27M
Link Fund Solutions Ltd
4.8M sh · $111.3M
Blackrock, Inc.
4.6M sh · $77.56M
Blackrock Inc.
3.8M sh · $32.06M
Irenic Capital Management LP
2.8M sh · $46.94M
Vanguard Group Inc
2.4M sh · $44.29M
Blackrock Fund Advisors
2.2M sh · $70.81M
Pictet Asset Management SA
1.8M sh · $19.06M
State Street Corp
1.3M sh · $22.59M

RATINGS SNAPSHOT

Overall rating: A-

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity5
Return On Assets5
Debt To Equity3
Price To Earnings2
Price To Book2
Overall Score4

TRADES BY CONGRESS

HOUSE TRADES
George Whitesides
George Whitesides
Sale (Full)
2025-03-24

INSIDER TRADES

★
OFFICER: SVP & CHIEF FINANCIAL OFFICER
Sawaf Aziz
Sale · 8.1K shares
2026-08-20
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Winningham Rick E
Sale · 20.0K shares
2026-08-20
★
OFFICER: SVP, DEV & HEAD OF IRE OFFICE
Miller Aine
Sale · 6.3K shares
2026-08-20
★
OFFICER: SVP, GEN COUNSEL AND SECRETARY
Grimaud Brett A.
Sale · 8.0K shares
2026-08-20

MOST RECENT ANALYST GRADES

GRADE SUMMARY
NEUTRAL 3
HOLD 2
PERFORM 1
6 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. NEUTRAL BTIG NEUTRAL Jones Trading HOLD B. Riley Securities NEUTRAL TD Cowen HOLD Oppenheimer PERFORM

SECTORS PEERS

PEERPRICE
VIR$10.83COMPARE
TYRA$24.94COMPARE
AVBP$30.17COMPARE
REPL$15.50COMPARE
GLUE$13.38COMPARE
BTX$8.96COMPARE
GERN$1.51COMPARE
VALN$6.43COMPARE